Bradykinin B2 receptor agonism: A novel therapeutic strategy for myocardial infarction

American Journal of Hypertension

Volumn 23, Issue 5, 2010, Pages 459-

  Duchene, Johan ^a   Bader, Michael ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ B2 RECEPTOR; BRADYKININ B2 RECEPTOR AGONIST; BRADYKININ B2 RECEPTOR ANTAGONIST; ICATIBANT;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE CELL; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; NONHUMAN; NOTE; PRIORITY JOURNAL; RAT; TRANSGENIC RAT; TREATMENT OUTCOME;

ANIMALS; BLOOD PRESSURE; CARDIOTONIC AGENTS; DISEASE MODELS, ANIMAL; MICE; MYOCARDIAL INFARCTION; RATS; RECEPTOR, BRADYKININ B2; STROKE VOLUME; VENTRICULAR REMODELING;

EID: 77951105518     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2010.32     Document Type: Note

References (4)

1. Miller AM, Katcher BS, Kotabe S. Racial disparities in hypertension control: not the provider but still a problem. Am J Hypertens, this issue.
2. Umscheid CA, Gross R, Weiner MG, Hollenbeak CS, Tang SS, Turner BJ. Racial disparities in hypertension control, but not treatment intensification. Am J Hypertens 2010; 23:54-61.
3. Norris K, Neutel JM. Emerging insights in the first-step use of antihypertensive combination therapy. J Clin Hypertens (Greenwich) 2007; 9(12 Suppl 5):5-14.
4. Rosen AB, Karter AJ, Liu JY, Selby JV, Schneider EC. Use of angiotensinconverting enzyme inhibitors and angiotensin receptor blockers in highrisk clinical and ethnic groups with diabetes. J Gen Intern Med 2004; 19:669-675.